Extraskeletal osteosarcoma is a rare cancer that produces bone or bone-like tissue inside soft tissues rather than within the skeleton itself. It accounts for roughly 2–4% of all osteosarcoma cases and about 1% of soft tissue sarcomas, with a yearly incidence hovering around 0.02 per 100,000 people.1PubMed Central. Epidemiological and clinicopathologic characteristics, and prognostic factors of patients with extra-skeletal osteosarcoma: a Surveillance, Epidemiology, and End Results population study Under a microscope, it looks identical to osteosarcoma that starts in bone, yet it behaves differently in important ways, and its treatment raises distinct questions that are still being worked out.2PubMed. Extraskeletal osteosarcoma: spectrum of imaging findings
What Extraskeletal Osteosarcoma Actually Is
Osteosarcoma is the most common primary bone cancer. The extraskeletal form, sometimes abbreviated ESOS, starts not in bone but in muscle, fat, connective tissue, or internal organs. It produces osteoid, which is the immature bone matrix that gives osteosarcoma its name, but does so in tissue that has no business making bone. Because it arises in soft tissue, it tends to present as a painless or mildly uncomfortable lump rather than as bone pain.
The distinction from conventional osteosarcoma matters because ESOS typically strikes an older population. While skeletal osteosarcoma peaks in teenagers and young adults, extraskeletal cases are far more common in middle-aged and older adults. A large review from M.D. Anderson Cancer Center found that presentations were usually an enlarging soft tissue mass, most often in the thigh, the upper extremity or shoulder area, or the retroperitoneum (the space behind the abdominal lining).3Cancer. Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases Tumor sizes varied widely in that series, from 2.5 cm to 30 cm. That range underscores one of the frustrations with ESOS: because the mass sits in soft tissue and often grows slowly at first, it can reach a substantial size before anyone notices.
Known and Suspected Causes
For most patients, no clear cause is identified. But two risk factors stand out in the literature.
The first is prior radiation therapy. Radiation-associated sarcoma is a recognized long-term complication of radiation treatment for other cancers, and ESOS is among the forms that can develop in a previously irradiated field. Case reports describe extraskeletal osteosarcomas arising in the chest wall muscles of patients who had received radiation for breast cancer, sometimes years or even decades after the original treatment.4PubMed. Radiation-associated extraskeletal osteosarcoma of the chest wall This does not mean radiation therapy is commonly dangerous. Radiation-induced sarcomas of any type are rare, and ESOS among them rarer still. But it does mean clinicians monitor previously irradiated areas with particular attention if a new mass appears.
The second risk factor is genetic. A molecular study examining the genomic landscape of ESOS found frequent losses in key tumor-suppressor genes. About 70% of tested tumors showed copy-number losses in the CDKN2A gene, roughly 56% in TP53, and around 49% in RB1. Mutations affecting pathways involved in gene regulation and cell signaling were also common.5PubMed Central. The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study In plain terms, these tumors tend to have multiple layers of genetic damage that disable the body’s normal brakes on cell growth. Whether patients carry inherited vulnerabilities to this damage or accumulate it randomly over a lifetime is still not fully understood, but the frequency of TP53 and RB1 losses echoes patterns seen in other aggressive sarcomas.
How It Typically Presents
The most common symptom is a growing lump, often in the deep soft tissue of the thigh, although ESOS can appear almost anywhere. A retroperitoneal case, for example, might show up on CT as a large calcified mass pressing on abdominal organs, sometimes found incidentally during imaging for unrelated complaints.6PubMed Central. Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma Pain, when present, tends to develop as the mass grows large enough to push on nerves or compress surrounding structures.
Because ESOS is so uncommon, it is rarely the first diagnosis on anyone’s mind. A soft tissue mass in an older adult is more likely to prompt consideration of a lipoma, a metastasis from another known cancer, or one of the more common soft tissue sarcomas. This diagnostic ambiguity is why imaging and biopsy play such critical roles.
What Imaging Reveals
Two features on imaging help point toward ESOS: the presence of mineralization within the mass and the tumor’s internal complexity. On CT scans, these tumors show soft tissue masses with uneven density, areas of cystic breakdown, and varying degrees of calcification or actual bone formation. The calcification tends to be scattered unevenly, sometimes clustered at the periphery and sometimes distributed throughout the tumor.7PubMed Central. Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma A two-center study of 54 patients found mineralization on CT in about 62% of cases, most of it in coarse, irregular clumps rather than fine speckles.8PubMed. Imaging presentation of extraskeletal osteosarcomas on CT and MRI and correlation with patients outcome
MRI adds crucial detail. Most tumors show relatively clear margins, and some have a visible capsule made up of tumor cells and fibrous tissue. The tumor’s solid portions tend to appear close to muscle signal on T1-weighted images and slightly brighter than muscle on T2-weighted images. Cystic breakdown is extremely common, and in some cases the cystic areas contain layered blood products visible as a fluid-fluid level, a finding that has also been described in telangiectatic osteosarcoma of bone.7PubMed Central. Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma Near-universal necrosis was noted in the two-center study, where 97% of tumors showed necrotic areas, and roughly four in five were highly variable in signal intensity.8PubMed. Imaging presentation of extraskeletal osteosarcomas on CT and MRI and correlation with patients outcome
None of these imaging features alone is diagnostic. Calcification inside a soft tissue mass can also be seen in myositis ossificans (a benign condition where muscle forms bone after injury), synovial sarcoma, and certain metastatic deposits. The combination of a large, internally complex, calcified soft tissue mass in an older adult raises the suspicion, but tissue sampling is always required.
How the Diagnosis Is Confirmed
Under the microscope, the key finding is malignant cells producing osteoid or bone within soft tissue, with no connection to the skeleton. All of the major subtypes known in skeletal osteosarcoma can appear in the extraskeletal form, including osteoblastic, chondroblastic, fibroblastic, telangiectatic, giant-cell-rich, and small-cell variants. Individual tumors often contain a mixture of these patterns, classified by whichever pattern dominates. The critical clue for pathologists is finding high-grade, mixed histology combined with osteoid or bone formation in a soft tissue mass.9Human Pathology Reports. Review Extraskeletal osteosarcoma and its histological mimics
The challenge is that several other soft tissue tumors can mimic ESOS. A fibroblastic variant might look like a garden-variety spindle cell sarcoma. A telangiectatic variant filled with blood-filled spaces could be confused with an aneurysmal bone cyst or certain vascular tumors. A giant-cell-rich variant may resemble an undifferentiated pleomorphic sarcoma with giant cells. Getting the diagnosis right matters because it changes treatment strategy, so pathologists often use immunohistochemistry and molecular testing alongside morphology.
Surgery as the Foundation of Treatment
Wide surgical removal of the tumor with clear (negative) margins is the primary treatment. Study after study links margin status to outcomes. In a European study of 266 patients, tumor size, margins, and age all emerged as significant factors in survival for the 211 patients who achieved complete surgical clearance.10PubMed. Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients A separate review of 53 cases found that patients with superficial tumors and negative margins had higher three-year event-free survival.11PubMed Central. Analysis of Outcomes in Extraskeletal Osteosarcoma: A Review of Fifty-three Cases And a Chinese single-center study identified positive margins, deep tumor location, and a mean tumor diameter of 5.5 cm or above as factors associated with worse survival.12Scientific Reports. Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China
Where the tumor sits determines how complex surgery becomes. A thigh mass may be approached much like any deep soft tissue sarcoma resection. A retroperitoneal tumor that abuts major blood vessels or organs presents a more daunting surgical problem. And a tumor of the hand or foot forces a painful decision between amputation and limb-sparing surgery. Reports suggest that limb conservation combined with radiation can achieve excellent local control with better functional outcomes and minimal added toxicity compared to amputation, at least for certain extremity locations.13PubMed Central. Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy
The Case for Radiation Therapy
Radiation therapy is used more often in extraskeletal osteosarcoma than in its skeletal counterpart, where osteosarcoma is traditionally considered radiation-resistant. The soft tissue context seems to change the equation. A study using national cancer registry data found that radiation therapy was significantly associated with decreased local recurrence, cutting the hazard roughly in half.14PubMed Central. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma That same analysis, however, did not find that radiation improved overall survival, just that it kept the disease from coming back at the original site.
A separate institutional series reported five-year local control of 93% when radiation was combined with surgery, with doses typically around 60 Gy either before or after the operation. Only one patient in that series experienced local recurrence.15American Journal of Clinical Oncology. Extraskeletal Osteosarcomas While those numbers look encouraging, it is worth remembering the sample sizes in ESOS studies are invariably small, given the rarity of the disease. The evidence is suggestive rather than definitive, but the trend consistently favors adding radiation to surgery for locally resectable tumors.
Chemotherapy and Its Uncertain Role
This is where the evidence gets contentious. ESOS sits at the intersection of two treatment traditions: the high-dose, multi-agent chemotherapy regimens developed for skeletal osteosarcoma (typically including drugs like methotrexate, doxorubicin, and cisplatin) and the regimens used for soft tissue sarcomas more broadly (often doxorubicin-based but at different doses and combinations). Clinicians have debated for years which approach fits ESOS better, if either does.
A meta-analysis comparing the two chemotherapy approaches found a modest advantage for osteosarcoma-type regimens. The five-year disease-free survival rate was about 56% with osteosarcoma-type chemotherapy versus roughly 45% with soft tissue sarcoma-type chemotherapy.16PubMed. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis That is an eleven-percentage-point difference in a pooled analysis, which matters, but the underlying studies were retrospective and small.
Whether chemotherapy improves survival at all is a more fundamental question. The registry-based study mentioned earlier found that chemotherapy did not decrease the risk of distant spread and was not associated with improved survival in localized ESOS.14PubMed Central. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma An institutional review observed a trend toward longer survival in patients who received chemotherapy compared to those who did not, but the difference did not reach statistical significance.17PubMed Central. The Treatment and Outcomes of Extraskeletal Osteosarcoma: Institutional Experience and Review of The Literature As a result, the role of chemotherapy remains a judgment call, often recommended for younger patients or those with high-grade, large, or deep tumors, but not universally accepted as standard the way it is for skeletal osteosarcoma in adolescents.
Emerging Drug Approaches
For patients whose disease progresses despite standard chemotherapy, newer targeted drugs are being studied. A network meta-analysis covering bone and soft tissue sarcomas found that adding small-molecule anti-angiogenic agents (drugs that cut off a tumor’s blood supply) to chemotherapy could improve disease control. Combinations involving anti-angiogenic drugs showed better disease control rates and objective response rates than chemotherapy alone in network comparisons, though these analyses grouped multiple sarcoma types together rather than isolating ESOS specifically.18PubMed Central. Efficacy and safety comparison of small molecule anti-angiogenic drugs in the treatment of bone and soft tissue sarcomas: a network meta-analysis Because ESOS is so rare, dedicated clinical trials for it alone are nearly impossible to run. Most evidence on newer drugs comes from basket trials or analyses that lump it in with related sarcomas.
Prognosis and What Drives It
ESOS carries a guarded prognosis compared to many other soft tissue sarcomas, and a worse prognosis than skeletal osteosarcoma in young patients. The single strongest predictor of outcome across multiple studies is tumor size. An international rare cancer network study found that tumors larger than 10 cm were an independent predictor of worse overall survival and disease-free survival. Older age was the other consistently significant factor.19PubMed Central. Soft Tissue Extraskeletal Osteosarcoma: An International Rare Cancer Network Study
The five-year disease-specific survival reported in the radiation series was 62%, and distant metastasis-free survival was 53%.15American Journal of Clinical Oncology. Extraskeletal Osteosarcomas Those figures roughly align with what other series report. In other words, just over half of patients remain free of distant spread at five years. The lungs are the most common site of metastasis, mirroring skeletal osteosarcoma.
Factors associated with better outcomes include superficial tumor location, smaller tumor size, negative surgical margins, and younger age. Among these, margin status is the one that treatment teams have the most control over, which is why surgery is planned so carefully and why re-excision is sometimes recommended when initial margins are uncertain.
Monitoring After Treatment
Local recurrence and metastasis rates remain high even after complete surgical removal, making surveillance essential.20PubMed Central. Case Report: Primary Extraskeletal Osteosarcoma in the Lung and Pulmonary Artery Follow-up typically involves periodic CT scans of the chest to watch for lung metastases and imaging of the original tumor site to detect local recurrence. PET/CT scanning using a radioactive glucose tracer has shown high sensitivity for detecting osteosarcoma recurrence generally, picking up abnormal uptake in about 89% of patients with confirmed recurrence in one series. Recurrence was detected at the original site alone in about a third of those patients, in the lungs alone in roughly a fifth, and at multiple sites in about a third.21PubMed. The role of (18)F-FDG PET/CT in the detection of osteosarcoma recurrence
There is no universally agreed-upon surveillance schedule for ESOS specifically. Most oncology teams adapt the follow-up protocols used for high-grade soft tissue sarcomas, which usually involve imaging every few months for the first two to three years and then at longer intervals. How long to continue surveillance is an open question, particularly because late recurrences have been documented.
Why ESOS Is So Difficult to Study
Nearly every paper on extraskeletal osteosarcoma begins by acknowledging the same problem: the disease is extraordinarily rare. With an incidence of roughly 0.02 per 100,000 people per year, even large cancer centers may see only a handful of cases over a decade.1PubMed Central. Epidemiological and clinicopathologic characteristics, and prognostic factors of patients with extra-skeletal osteosarcoma: a Surveillance, Epidemiology, and End Results population study That means almost all published evidence comes from retrospective reviews, case series, and population-based registry studies. Randomized controlled trials, the gold standard for treatment questions, are essentially nonexistent for this diagnosis.
This has practical consequences for patients and clinicians. Treatment recommendations are often borrowed from skeletal osteosarcoma or from general soft tissue sarcoma guidelines and then adapted based on expert opinion and the limited ESOS-specific data available. Two experienced sarcoma centers may reasonably reach different conclusions about whether a particular patient should receive chemotherapy, because the evidence genuinely supports multiple interpretations. Patients benefit from being treated at centers with sarcoma expertise, where multidisciplinary tumor boards can weigh the ambiguous evidence collectively. International collaboration, including rare cancer networks and shared registries, remains the most realistic path toward stronger evidence for this uncommon disease.